3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, Marco Colleoni, Agostina Stradella, Begoña Bermejo, Florence Dalenc, Santiago Escrivá-de-Romaní, Lourdes Calvo Martínez, Nuria Ribelles, Frederik Marmé, Alfonso Cortés, Cinta Albacar, Geraldine Gebhart, Aleix Prat, Khaldoun Kerrou, Peter Schmid, Sofia Braga, Serena Di Cosimo, Maria Gion, Gabriele Antonarelli, Crina Popa, Emilia Szostak, Daniel Alcalá-López, Petra Gener, Jose Rodríguez-Morató, Leonardo Mina, Miguel Sampayo-Cordero, Antonio Llombart-Cussac

Open source

DOI: 10.1016/s0140-6736(24)00054-0
Published: 2024-04
Container: The Lancet
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-24-00054-0,
  title = {3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial},
  author = {José Manuel Pérez-García and Javier Cortés and Manuel Ruiz-Borrego and Marco Colleoni and Agostina Stradella and Begoña Bermejo and Florence Dalenc and Santiago Escrivá-de-Romaní and Lourdes Calvo Martínez and Nuria Ribelles and Frederik Marmé and Alfonso Cortés and Cinta Albacar and Geraldine Gebhart and Aleix Prat and Khaldoun Kerrou and Peter Schmid and Sofia Braga and Serena Di Cosimo and Maria Gion and Gabriele Antonarelli and Crina Popa and Emilia Szostak and Daniel Alcalá-López and Petra Gener and Jose Rodríguez-Morató and Leonardo Mina and Miguel Sampayo-Cordero and Antonio Llombart-Cussac},
  year = {2024},
  journal = {The Lancet},
  doi = {10.1016/s0140-6736(24)00054-0},
  url = {https://doi.org/10.1016/s0140-6736(24)00054-0}
}

RIS

TY  - JOUR
TI  - 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
AU  - José Manuel Pérez-García
AU  - Javier Cortés
AU  - Manuel Ruiz-Borrego
AU  - Marco Colleoni
AU  - Agostina Stradella
AU  - Begoña Bermejo
AU  - Florence Dalenc
AU  - Santiago Escrivá-de-Romaní
AU  - Lourdes Calvo Martínez
AU  - Nuria Ribelles
AU  - Frederik Marmé
AU  - Alfonso Cortés
AU  - Cinta Albacar
AU  - Geraldine Gebhart
AU  - Aleix Prat
AU  - Khaldoun Kerrou
AU  - Peter Schmid
AU  - Sofia Braga
AU  - Serena Di Cosimo
AU  - Maria Gion
AU  - Gabriele Antonarelli
AU  - Crina Popa
AU  - Emilia Szostak
AU  - Daniel Alcalá-López
AU  - Petra Gener
AU  - Jose Rodríguez-Morató
AU  - Leonardo Mina
AU  - Miguel Sampayo-Cordero
AU  - Antonio Llombart-Cussac
PY  - 2024
JO  - The Lancet
DO  - 10.1016/s0140-6736(24)00054-0
UR  - https://doi.org/10.1016/s0140-6736(24)00054-0
ER  -

APA

Pérez-García, J. M., Cortés, J., Ruiz-Borrego, M., Colleoni, M., Stradella, A., Bermejo, B., Dalenc, F., Escrivá-de-Romaní, S., Martínez, L. C., Ribelles, N., Marmé, F., Cortés, A., Albacar, C., Gebhart, G., Prat, A., Kerrou, K., Schmid, P., Braga, S., Cosimo, S. D., Gion, M., Antonarelli, G., Popa, C., Szostak, E., Alcalá-López, D., Gener, P., Rodríguez-Morató, J., Mina, L., Sampayo-Cordero, M., & Llombart-Cussac, A. (2024). 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(24)00054-0

Source records

crossref · retrieved 2026-09-25T17:32:10.613Z